◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksF › FTRE

Fortrea Holdings Inc. (FTRE) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-13

Fortrea Holdings Inc. (FTRE) operates in the BIOTECHNOLOGY industry and is headquartered in Durham, United States with about 14,000 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, FTRE reported $2.7B in revenue and ($986M) in net income.

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.

Interactive charts & full statements → Open the FTRE valuation workbench →

FTRE Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Total Revenue$2.7B$2.7B$2.7B$2.8B$2.8B$3.1B$2.6B
Gross Profit$458M$426M$534M$591M$724M$604M$489M
Gross Margin %17.1%15.6%19.8%20.8%25.5%19.8%19.0%
Operating Income (EBIT)$11M($31M)($162M)$32M$187M$114M($314M)
Operating Margin %0.4%-1.1%-6.0%1.1%6.6%3.7%-12.2%
Net Income($85M)($986M)($328M)($25M)$186M$98M($359M)
Net Margin %-3.2%-36.2%-12.2%-0.9%6.6%3.2%-13.9%
EBITDA$81M($814M)($64M)$137M$281M$303M$222M
Earnings Per Share (EPS)$-0.93$-10.81$-3.67$-0.28$2.11$1.11$-4.06
Shares Outstanding (M)94M91M90M89M88M88M88M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FTRE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$678M$636M$660M$701M$710M$651M$697M$675M
Gross Profit$139M$104M$112M$103M$114M$116M$141M$148M
Gross Margin %20.5%16.3%16.9%14.7%16.0%17.9%20.2%22.0%
Operating Income (EBIT)$15M$3M$9M($16M)($11M)($520M)($56M)($18M)
Operating Margin %2.2%0.5%1.3%-2.3%-1.5%-79.9%-8.0%-2.7%
Net Income($13M)($24M)($32M)($16M)($375M)($563M)($61M)($28M)
Net Margin %-1.9%-3.7%-4.9%-2.3%-52.8%-86.4%-8.8%-4.1%
EBITDA$34M$26M$7M$14M($328M)($506M)($32M)$8M
Earnings Per Share (EPS)$-0.14$-0.26$-0.36$-0.17$-4.14$-6.30$-0.68$-0.31
Shares Outstanding (M)94M91M91M91M91M89M90M90M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FTRE Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash from Operations (CFO)$182M$114M$263M$168M$83M$170M$201M
Capital Expenditures (CapEx)$32M$25M$26M$40M$54M$26M$24M
Free Cash Flow (FCF)$151M$88M$237M$128M$28M$143M$177M
FCF Margin %5.6%3.2%8.8%4.5%1.0%4.7%6.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FTRE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($16M)($17M)$129M$87M$22M($124M)$17M($2M)
Capital Expenditures (CapEx)$9M$8M$8M$7M$8M$3M$3M$8M
Free Cash Flow (FCF)($26M)($25M)$122M$80M$14M($127M)$14M($11M)
FCF Margin %-3.8%-3.9%18.4%11.3%2.0%-19.5%2.0%-1.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FTRE Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$2.7B$2.7B$3.6B$4.3B$4.3B$4.4B
Cash & Cash Equivalents$169M$175M$118M$109M$112M$95M
Total Liabilities$2.2B$2.2B$2.2B$2.6B$945M$1.1B
Total Debt (Short + Long-Term)$1.1B$1.1B$1.1B$1.6B$23M$24M
Total Shareholders' Equity$524M$564M$1.4B$1.7B$3.3B$3.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FTRE viewer.

Other Companies in BIOTECHNOLOGY

← FTRBAll “F” companiesFTRI →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.